Stiff Person Syndrome Epidemiology Forecast 2026-2035

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

Italy and Spain

High-Risk Population

Adults, particularly women, with progressive axial or limb stiffness, stimulus-sensitive painful spasms, gait impairment, unexplained falls, or coexisting autoimmune disease: especially type 1 diabetes mellitus and autoimmune thyroid disease.

Key Diagnostic Method

Diagnosis requires clinical assessment supported by electromyography demonstrating continuous motor-unit activity, appropriate serum/CSF antibody testing, and exclusion of competing neurological diagnoses. High-titer GAD65 antibodies strongly support classic SPS; glycine-receptor and amphiphysin antibodies are important in selected spectrum and paraneoplastic phenotypes.

Major Risk Factor

Autoimmune susceptibility with antibodies against inhibitory neuronal proteins, principally GAD65, glycine receptor, or amphiphysin. SPS is frequently associated with other autoimmune diseases, particularly type 1 diabetes and autoimmune thyroid disease.

Major gap in the market

Diagnostic delay and misdiagnosis, lack of internationally standardized diagnostic criteria, limited epidemiological surveillance, incomplete response to existing therapies, and absence of an approved disease-modifying therapy.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

The best contemporary population-based estimate is the 2024 Colorado study's 2.11 per 100,000 SPSD prevalence, with stricter diagnostic definitions producing 1.36–1.82 per 100,000. Japan's nationwide survey estimated 257 SPS patients and a period prevalence of 0.20 per 100,000. These estimates are not directly interchangeable because of differing definitions.

Gender-Specific Cases of the Disease

SPS predominantly affects women. In the 2025 diagnostic case-control cohort, 76.4% were female; in the 2023 Johns Hopkins cohort, women represented 75%. The Japanese nationwide GAD65-positive cohort contained 23 women among 30 detailed cases (76.7%).

Age-Specific Cases of the Disease

SPS is primarily an adult-onset disease. In Japan, median age at onset was 51 years, with a range of 26–83 years. In the 2025 Mayo long-term cohort, median onset was 45 years, range 16–78. Pediatric disease is distinctly uncommon; a 2025 systematic review identified only 49 pediatric cases from 41 reports across 15 countries.

Ethnicity-Wise Cases of the Disease

Available cohorts demonstrate SPS across racial and ethnic groups but do not establish ethnicity-specific incidence. The 2024 Colorado cohort included a diverse population; a 2025 case-control cohort was 70.8% White, reflecting referral-cohort composition rather than disease-specific racial risk.

Mortality and Survival Analysis of the Disease

Contemporary population-level mortality estimates are unavailable. Long-term disease can cause severe disability, falls, respiratory complications, and secondary complications from immobility. In the 2025 Mayo cohort, half of patients became functionally dependent at disease nadir, but 67% were functionally independent at last follow-up after treatment. Pediatric literature reported persistent symptoms in 26.5% of cases.

Disease Type

Prevalence

Classic Stiff Person Syndrome

The predominant SPS phenotype, characterized by progressive stiffness and rigidity predominantly affecting the axial and proximal limb musculature, with painful spasms precipitated by sudden movement, tactile or auditory stimuli, or emotional stress. Classic SPS is generally associated with high-titer GAD65 antibodies. It represents approximately 70–80% of SPS cases in clinical descriptions.

SPS-Plus

A classic SPS phenotype accompanied by additional neurological manifestations such as cerebellar ataxia, brainstem abnormalities, epilepsy, or other focal neurological features. The 2023 Johns Hopkins cohort classified 18% of its SPSD patients as SPS-plus.

Stiff-Limb Syndrome

A focal or regional SPS phenotype in which rigidity and painful spasms predominantly affect one or more limbs rather than the classic axial distribution. It may progress to more generalized SPS. The Japanese nationwide survey found 30% of GAD65-positive SPS patients had stiff-limb syndrome, while the 2025 Mayo long-term cohort identified four stiff-limb cases among 43 patients.

Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM)

A severe SPS-spectrum phenotype characterized by rigidity and painful spasms accompanied by myoclonus and brainstem/autonomic or encephalopathic features. Glycine-receptor antibodies are particularly associated with PERM. The 2025 pediatric systematic review identified PERM in 22.4% of reported pediatric SPS-spectrum cases, although this figure should not be extrapolated to the overall SPS population.

Country

Key Insights

United States

The strongest contemporary epidemiological evidence comes from the United States. A 2024 Colorado population-based study estimated SPSD prevalence at 2.11 per 100,000 and annual incidence at 0.35 per 100,000 person-years during 2012–2022. A separate 2025 diagnostic cohort contained 199 SPSD cases, 154 classic SPS and 45 SPS-plus, with 76.4% female. A 2025 Mayo long-term study included 43 GAD65-positive patients and showed substantial disability at disease nadir but functional recovery in many treated patients.

Germany

The historically cited German estimate of approximately one case per million originated from a Heidelberg single-center experience and predates the current epidemiological literature. Contemporary U.S. data now indicate that this historical figure likely substantially underestimates the burden of SPSD.

France

French evidence contributes to the broader European SPS literature, but available specialist cohorts do not provide a defensible national patient count

Italy

Italy contributed to the 2025 systematic review of rituximab in GAD65-positive SPS, which included 30 patients across 14 studies; the evidence suggested clinical improvement in many patients but remained limited by small samples and heterogeneous treatment protocols.

Spain

Available Spanish literature consists predominantly of specialist clinical reports rather than national surveillance, preventing a reliable national case estimate.

United Kingdom

Contemporary UK-specific population data remain limited. The historical British Neurological Surveillance Unit study identified 119 cases over five years, corresponding to an estimated prevalence of approximately 1–2 per million, but this surveillance period was 2000–2005 and therefore is not a contemporary prevalence estimate.

Japan

A 2023 nationwide survey provides the strongest contemporary country-specific estimate outside the United States. It estimated 257 SPS patients, corresponding to a period prevalence of 0.20 per 100,000, while GAD65-positive SPS was estimated at 140 patients, or 0.11 per 100,000. Among 30 detailed GAD65-positive cases, 76% were female, median onset was 51 years, and 70% had classic SPS while 30% had stiff-limb syndrome.

India

A 2024 Indian series from SMS Medical College, Jaipur, comprised 17 reported SPS/SPS-spectrum cases, including 16 classic SPS and one stiff-limb syndrome. The median presentation age was 43 years, 88% were adults, and the cohort included eight women and nine men. The authors also reviewed 16 previously reported Indian cases. These data demonstrate established clinical recognition but do not support a national prevalence estimate.